Dextromethorphan and guaifenesin use should be monitored diligently in individuals with "poor metabolizer" CYP2D6 enzyme levels and individuals who are sedated. This mix medication includes a significant median harmful dose (TD50) to median productive dose (ED50) ratio (or therapeutic index) in these clients. Often times this drug is taken on https://hubwebsites.com/story19460242/5-simple-techniques-for-dextromethorphan-dxm-for-sale-in-europe